巣状分節性糸球体硬化症（FSGS）治療の世界市場（～2026年）

• 英文タイトル：Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY11975
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、94ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は巣状分節性糸球体硬化症（FSGS）治療のグローバル市場について調査・分析したレポートです。種類別（薬物療法、透析、腎移植）市場規模、用途別（一次FSGS、二次FSGS）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別巣状分節性糸球体硬化症（FSGS）治療の競争状況、市場シェア
・世界の巣状分節性糸球体硬化症（FSGS）治療市場：種類別市場規模 2015年-2020年（薬物療法、透析、腎移植）
・世界の巣状分節性糸球体硬化症（FSGS）治療市場：種類別市場規模予測 2021年-2026年（薬物療法、透析、腎移植）
・世界の巣状分節性糸球体硬化症（FSGS）治療市場：用途別市場規模 2015年-2020年（一次FSGS、二次FSGS）
・世界の巣状分節性糸球体硬化症（FSGS）治療市場：用途別市場規模予測 2021年-2026年（一次FSGS、二次FSGS）
・北米の巣状分節性糸球体硬化症（FSGS）治療市場分析：米国、カナダ
・ヨーロッパの巣状分節性糸球体硬化症（FSGS）治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの巣状分節性糸球体硬化症（FSGS）治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の巣状分節性糸球体硬化症（FSGS）治療市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの巣状分節性糸球体硬化症（FSGS）治療市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：B. Braun Melsungen、Medtronic、Pfizer、Complexa、Dimerix、Retrophin、Beckman Coulter Inc. (Danaher)、Boston Scientific Corporation、ChemoCentryx、Variant Pharmaceuticals
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Focal segmental glomerulosclerosis (FSGS) is a type of rare kidney disease that affects the kidney’s filtering system (glomeruli) resulting in proteinuria and serious scarring. Focal segmental glomerulosclerosis (FSGS) is usually fatal since it causes kidney failure within four to nine years followed by dialysis and then death. FSGS advances much more swiftly than diabetic nephropathy. Massive proteinuria, nephrotic syndrome, edema, hyperlipidemia, and hypoalbuminemia are some of the common symptoms of the disease. Risk factors include obesity, infection, sickle cell disease and reflux nephropathy.
The market for FSGS treatment is primarily driven by the increasing disease burden, rising focus towards rare diseases, and increased R&D activity. Geographical analysis shows that North America is expected to maintain its dominance in this market, particularly due to well-structured healthcare facilities, early adoption of therapies and diagnosis options, and better reimbursement policies, as compared to other regions.

Market Analysis and Insights: Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
The global Focal Segmental Glomerulosclerosis (FSGS) Treatment market size is projected to reach US$ 322.7 million by 2026, from US$ 308.5 million in 2020, at a CAGR of 4.3%% during 2021-2026.

Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Scope and Market Size
Focal Segmental Glomerulosclerosis (FSGS) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
B. Braun Melsungen
Medtronic
Pfizer
Complexa
Dimerix
Retrophin
Beckman Coulter Inc. (Danaher)
Boston Scientific Corporation
ChemoCentryx
Variant Pharmaceuticals

Market segment by Type, the product can be split into
Drug Therapy
Dialysis
Kidney Transplant
Market segment by Application, split into
Primary FSGS
Secondary FSGS

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue
1.4 Market by Type
1.4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Drug Therapy
1.4.3 Dialysis
1.4.4 Kidney Transplant
1.5 Market by Application
1.5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Primary FSGS
1.5.3 Secondary FSGS
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Perspective (2015-2026)
2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Growth Trends by Regions
2.2.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Focal Segmental Glomerulosclerosis (FSGS) Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Market Size
3.1.1 Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Revenue (2015-2020)
3.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Concentration Ratio
3.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue in 2019
3.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players Head office and Area Served
3.4 Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Solution and Service
3.5 Date of Enter into Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020)
5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2015-2020)
6.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players in North America (2019-2020)
6.3 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020)
6.4 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2015-2020)
7.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players in Europe (2019-2020)
7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020)
7.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020)

8 China
8.1 China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2015-2020)
8.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players in China (2019-2020)
8.3 China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020)
8.4 China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2015-2020)
9.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players in Japan (2019-2020)
9.3 Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020)
9.4 Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2015-2020)
10.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020)

11 India
11.1 India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2015-2020)
11.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players in India (2019-2020)
11.3 India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020)
11.4 India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2015-2020)
12.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 B. Braun Melsungen
13.1.1 B. Braun Melsungen Company Details
13.1.2 B. Braun Melsungen Business Overview
13.1.3 B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.1.4 B. Braun Melsungen Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020))
13.1.5 B. Braun Melsungen Recent Development
13.2 Medtronic
13.2.1 Medtronic Company Details
13.2.2 Medtronic Business Overview
13.2.3 Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.2.4 Medtronic Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020)
13.2.5 Medtronic Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.3.4 Pfizer Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Complexa
13.4.1 Complexa Company Details
13.4.2 Complexa Business Overview
13.4.3 Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.4.4 Complexa Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020)
13.4.5 Complexa Recent Development
13.5 Dimerix
13.5.1 Dimerix Company Details
13.5.2 Dimerix Business Overview
13.5.3 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.5.4 Dimerix Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020)
13.5.5 Dimerix Recent Development
13.6 Retrophin
13.6.1 Retrophin Company Details
13.6.2 Retrophin Business Overview
13.6.3 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.6.4 Retrophin Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020)
13.6.5 Retrophin Recent Development
13.7 Beckman Coulter Inc. (Danaher)
13.7.1 Beckman Coulter Inc. (Danaher) Company Details
13.7.2 Beckman Coulter Inc. (Danaher) Business Overview
13.7.3 Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.7.4 Beckman Coulter Inc. (Danaher) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020)
13.7.5 Beckman Coulter Inc. (Danaher) Recent Development
13.8 Boston Scientific Corporation
13.8.1 Boston Scientific Corporation Company Details
13.8.2 Boston Scientific Corporation Business Overview
13.8.3 Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.8.4 Boston Scientific Corporation Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020)
13.8.5 Boston Scientific Corporation Recent Development
13.9 ChemoCentryx
13.9.1 ChemoCentryx Company Details
13.9.2 ChemoCentryx Business Overview
13.9.3 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.9.4 ChemoCentryx Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020)
13.9.5 ChemoCentryx Recent Development
13.10 Variant Pharmaceuticals
13.10.1 Variant Pharmaceuticals Company Details
13.10.2 Variant Pharmaceuticals Business Overview
13.10.3 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
13.10.4 Variant Pharmaceuticals Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020)
13.10.5 Variant Pharmaceuticals Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue
Table 3. Ranking of Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Drug Therapy
Table 6. Key Players of Dialysis
Table 7. Key Players of Kidney Transplant
Table 8. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Regions (2015-2020)
Table 12. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Growth Strategy
Table 18. Main Points Interviewed from Key Focal Segmental Glomerulosclerosis (FSGS) Treatment Players
Table 19. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Players (2015-2020) (Million US$)
Table 20. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Players (2015-2020)
Table 21. Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment as of 2019)
Table 22. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Solution and Service
Table 25. Date of Enter into Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 28. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Share by Type (2015-2020)
Table 29. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Type (2021-2026)
Table 30. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Share by Application (2015-2020)
Table 31. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 32. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Share by Application (2021-2026)
Table 33. North America Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share (2019-2020)
Table 35. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2015-2020)
Table 37. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2015-2020)
Table 39. Europe Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share (2019-2020)
Table 41. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2015-2020)
Table 43. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2015-2020)
Table 45. China Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (2019-2020) (Million US$)
Table 46. China Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share (2019-2020)
Table 47. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2015-2020)
Table 49. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2015-2020)
Table 51. Japan Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share (2019-2020)
Table 53. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2015-2020)
Table 55. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share (2019-2020)
Table 59. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2015-2020)
Table 61. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2015-2020)
Table 63. India Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (2019-2020) (Million US$)
Table 64. India Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share (2019-2020)
Table 65. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2015-2020)
Table 67. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share (2019-2020)
Table 71. Central & South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2015-2020)
Table 73. Central & South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2015-2020)
Table 75. B. Braun Melsungen Company Details
Table 76. B. Braun Melsungen Business Overview
Table 77. B. Braun Melsungen Product
Table 78. B. Braun Melsungen Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 79. B. Braun Melsungen Recent Development
Table 80. Medtronic Company Details
Table 81. Medtronic Business Overview
Table 82. Medtronic Product
Table 83. Medtronic Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 84. Medtronic Recent Development
Table 85. Pfizer Company Details
Table 86. Pfizer Business Overview
Table 87. Pfizer Product
Table 88. Pfizer Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 89. Pfizer Recent Development
Table 90. Complexa Company Details
Table 91. Complexa Business Overview
Table 92. Complexa Product
Table 93. Complexa Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 94. Complexa Recent Development
Table 95. Dimerix Company Details
Table 96. Dimerix Business Overview
Table 97. Dimerix Product
Table 98. Dimerix Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 99. Dimerix Recent Development
Table 100. Retrophin Company Details
Table 101. Retrophin Business Overview
Table 102. Retrophin Product
Table 103. Retrophin Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 104. Retrophin Recent Development
Table 105. Beckman Coulter Inc. (Danaher) Company Details
Table 106. Beckman Coulter Inc. (Danaher) Business Overview
Table 107. Beckman Coulter Inc. (Danaher) Product
Table 108. Beckman Coulter Inc. (Danaher) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 109. Beckman Coulter Inc. (Danaher) Recent Development
Table 110. Boston Scientific Corporation Business Overview
Table 111. Boston Scientific Corporation Product
Table 112. Boston Scientific Corporation Company Details
Table 113. Boston Scientific Corporation Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 114. Boston Scientific Corporation Recent Development
Table 115. ChemoCentryx Company Details
Table 116. ChemoCentryx Business Overview
Table 117. ChemoCentryx Product
Table 118. ChemoCentryx Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 119. ChemoCentryx Recent Development
Table 120. Variant Pharmaceuticals Company Details
Table 121. Variant Pharmaceuticals Business Overview
Table 122. Variant Pharmaceuticals Product
Table 123. Variant Pharmaceuticals Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2015-2020) (Million US$)
Table 124. Variant Pharmaceuticals Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Drug Therapy Features
Figure 3. Dialysis Features
Figure 4. Kidney Transplant Features
Figure 5. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application: 2020 VS 2026
Figure 6. Primary FSGS Case Studies
Figure 7. Secondary FSGS Case Studies
Figure 8. Focal Segmental Glomerulosclerosis (FSGS) Treatment Report Years Considered
Figure 9. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Regions: 2020 VS 2026
Figure 11. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Players in 2019
Figure 14. Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue in 2019
Figure 16. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed

以下、関連資料のご紹介

巣状分節性糸球体硬化症（FSGS）の世界市場（～2026年）

Global Focal Segmental Glomerulosclerosis (FSGS) Market Insights and Forecast to 2026
MRC2-11QY06364 2020年11月20日 114Pages
当調査資料は巣状分節性糸球体硬化症（FSGS）のグローバル市場について調査・分析したレポートです。種類別（原発性巣状分節性糸球体硬化症、続発性巣状分節性糸球体硬化症）市場規模、用途別（病院、外来外科センター、専門クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...

巣状分節性糸球体硬化症薬の世界市場（～2026年）

Global Focal Segmental Glomerulosclerosis Drug Market Insights and Forecast to 2026
MRC2-11QY06365 2020年11月20日 118Pages
当調査資料は巣状分節性糸球体硬化症薬のグローバル市場について調査・分析したレポートです。種類別（ロスマピモド、SHP-627、スパルセンタン、TM-5484、その他）市場規模、用途別（クリニック、研究センター、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...

多形性膠芽腫（GBM）治療の世界市場（～2026年）

Global Glioblastoma Multiforme Treatment (GBM) Market Size, Status and Forecast 2020-2026
MRC2-11QY12056 2020年11月25日 92Pages
当調査資料は多形性膠芽腫（GBM）治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、放射線療法、遺伝子治療、分子バイオテクノロジー）市場規模、用途別（ベバコズマブ、カルムスチン、テモゾロミド）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリ...

神経精神障害・治療の世界市場（～2026年）

Global Neuropsychiatric Disorders And Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY03957 2020年11月20日 97Pages
当調査資料は神経精神障害・治療のグローバル市場について調査・分析したレポートです。種類別（変性疾患、神経症、精神病）市場規模、用途別（病院、診療所、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オースト...

グロボイド細胞白質ジストロフィー（GLD）治療の世界市場（～2026年）

Global Globoid Cell Leukodystrophy Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12059 2020年11月25日 93Pages
当調査資料はグロボイド細胞白質ジストロフィー（GLD）治療のグローバル市場について調査・分析したレポートです。種類別（RND-001、CMB-200、DUOC-01、その他）市場規模、用途別（病院、クリニック、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...

癲癇診断・治療の世界市場（～2026年）

Global Epilepsy Diagnosis & Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY11874 2020年11月25日 91Pages
当調査資料は癲癇診断・治療のグローバル市場について調査・分析したレポートです。種類別（診断（神経学的検査・血液検査・画像診断）、治療（医学・手術））市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、...

経口血糖降下薬（OAD）治療の世界市場（～2026年）

Global Oral Antidiabetic (OAD) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04077 2020年11月20日 99Pages
当調査資料は経口血糖降下薬（OAD）治療のグローバル市場について調査・分析したレポートです。種類別（スルホニル尿素剤、ビグアニド、腸内α-グルコシダーゼ阻害剤、その他）市場規模、用途別（病院、クリニック、糖尿病治療センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、...

HIV診断・治療の世界市場（～2026年）

Global HIV Diagnosis & Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12200 2020年11月25日 95Pages
当調査資料はHIV診断・治療のグローバル市場について調査・分析したレポートです。種類別（ELISA検査、唾液検査、ウイルス量検査、ウエスタンブロット、その他）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日...

脱毛症（脱毛）治療の世界市場（～2026年）

Global Alopecia (Hair Loss)Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY13657 2020年11月30日 95Pages
当調査資料は脱毛症（脱毛）治療のグローバル市場について調査・分析したレポートです。種類別（ビタミン・サプリメント、シャンプー・コンディショナー、その他）市場規模、用途別（男性、女性、子供）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中...

髄膜炎診断・治療の世界市場（～2026年）

Global Meningitis Diagnosis and Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12650 2020年11月25日 91Pages
当調査資料は髄膜炎診断・治療のグローバル市場について調査・分析したレポートです。種類別（血液培養、イメージング、腰椎穿刺）市場規模、用途別（病院・クリニック、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド...

巣状分節性糸球体硬化症（FSGS）の世界市場（～2026年） Focal Segmental Glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults. Market Analysis and Insights: Global Focal Segmental Glomerulosclerosis (FSGS) Market The global Focal Segmental Glomerulosclerosis (FSGS) m…
巣状分節性糸球体硬化症薬の世界市場（～2026年） Market Analysis and Insights: Global Focal Segmental Glomerulosclerosis Drug Market The global Focal Segmental Glomerulosclerosis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Focal Segmental Glomerulosclerosis …
フォーカルアドヒージョンキナーゼの世界市場（～2026年） Market Analysis and Insights: Global Focal Adhesion Kinase Market The global Focal Adhesion Kinase market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Focal Adhesion Kinase Scope and Market Size Focal Adhesion Kinase marke…
体外血液治療の世界市場（～2026年） The extracorporeal blood treatment is a type of filtration method used to remove many toxins from the blood. The demand for extracorporeal blood treatment is expected to upsurge owing to the growth of kidney diseases. Market Analysis and Insights: Global Extracorporeal Blood Treatment Market The glo…
末期腎疾患治療の世界市場（～2026年） Market Analysis and Insights: Global End-Stage Kidney Disease Treatment Market The global End-Stage Kidney Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global End-Stage Kidney Disease Treatment Scope and …